Two New Reviews Count the Human Evidence for BPC-157. It Comes to 30 People.

BPC-157 is one of the most-discussed research peptides of the last decade. It is a synthetic chain of 15 amino acids based on a fragment of a protein found in gastric juice, and it has been the subject of hundreds of laboratory and animal papers. Two reviews published in October 2026 asked a narrower question: how much of that work was done in people?

The answer, from both, is very little.

The systematic review: three studies, 30 participants

A team writing in Acta Orthopaedica Belgica ran a formal systematic review, registered in advance with the PROSPERO database, searching Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to 1 June 2026. They looked for any study of BPC-157 in human participants, for any purpose.

They found three, with 30 participants between them:

Study	Design	Participants
Knee pain	Retrospective, no control group	16
Interstitial cystitis (a bladder condition)	Retrospective pilot, no control group	12
Intravenous safety	Prospective pilot	2

All three reported that most participants improved and that no treatment-related adverse events were recorded. The reviewers then graded the evidence using GRADE, the standard framework for rating how far a body of evidence can be trusted. All three studies were judged to be of poor methodological quality, and the overall certainty of evidence was rated very low, because of serious risk of bias, indirectness and imprecision.

That rating matters more than the reported improvements. A retrospective study without a control group cannot separate the effect of a compound from natural recovery, placebo response or other care the participants received at the same time. With 30 people across three different conditions, a rare adverse event would be unlikely to show up at all.

The authors concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality clinical trials.

The orthopaedic review: same picture from another angle

Writing in the Journal of the American Academy of Orthopaedic Surgeons, surgeons from NYU Langone and Baptist Health South Florida reviewed BPC-157 alongside thymosin beta-4 and TB-500. Their searches ran through June 2026 and included regulatory and anti-doping sources.

They describe BPC-157 as having the largest body of direct musculoskeletal preclinical evidence of the three, mostly small-animal studies of tendon, ligament, muscle, joint inflammation and bone. They also state that human musculoskeletal evidence is limited to one small, retrospective, uncontrolled case series without validated outcome measures, and that pharmacokinetic and long-term safety data are lacking. They note that none of the three compounds has an FDA-approved musculoskeletal indication.

Why the animal record does not settle it

The preclinical literature is large but uneven. A separate critical review in the International Journal of Molecular Sciences this September examined BPC-157 in rodent ischemia-reperfusion models, where blood flow is cut off and then restored. It found consistent reports of reduced oxidative and inflammatory markers, but also short observation periods, single-dose designs and incompletely reported risk of bias. It called BPC-157 a hypothesis-generating candidate and listed what has not yet been done: independent blinded replication, dose-response work, pharmacokinetic characterisation, rigorous toxicology and, finally, controlled human studies.

A scoping review in The American Journal of Sports Medicine in August reached a similar conclusion across six popular peptides: two-thirds of the identified publications used animal models, and human studies mostly lacked robust controls.

What has not been studied

No randomised, controlled trial of BPC-157 in humans appears in any of these reviews.
No long-term human safety data exist.
How BPC-157 is absorbed, distributed and cleared in people has not been characterised.

What to watch

The useful signal from here is not another animal study but a registered, controlled human trial with published methods and outcomes. We will report one if and when it appears.